Peptide Encyclopedia / Mazdutide
EncyclopediaMazdutide is a dual glucagon and GLP-1 receptor agonist, an oxyntomodulin analog that pairs appetite suppression with glucagon-driven energy expenditure and liver fat reduction. It stays investigational in phase 2 and 3 trials, developed by Innovent and Eli Lilly, with no FDA approval. Below you'll find reported dosing, reconstitution, safety, and legal status. Educational only, not medical advice.
| Category | GLP-1 / Metabolic |
| Regulatory status | Investigational; not FDA-approved. |
A dual glucagon receptor (GCGR) and GLP-1 receptor agonist (an oxyntomodulin analog), combining appetite suppression and glycemic benefit with glucagon-mediated increases in energy expenditure and hepatic fat reduction.
uncertain from public data; engineered for once-weekly subcutaneous dosing. Commonly reported use/dosing: No approved protocol. In trials administered as once-weekly subcutaneous injection with dose escalation; not a validated or prescribable regimen outside studies.
Investigational; not FDA-approved. Developed by Innovent/Eli Lilly, with regulatory activity centered in China for obesity/type 2 diabetes. Not approved in the US.
GI effects typical of incretins (nausea, vomiting, diarrhea, decreased appetite); glucagon-agonism raises theoretical concerns about heart rate and glucose handling. Long-term safety not established.
Phase 2/3 clinical development; not yet approved (most advanced regulatory progress in China).
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Mazdutide may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
